Galectin-3 as a Marker and Potential Therapeutic Target in Breast Cancer
Figure 3
ATO treatment (2.5 µM) significantly increased endogenous galectin-3 expression in MDA-MB-231 cells.
Cells were treated with ATO and anti-galectin-3 antibody (1∶1000) was used to detect endogenous galectin-3 proteins. GAPDH was used as loading control. The results shown are the mean of at least 3 independent experiments. *P<0.01.